Fierce Biotech Fundraising Tracker '26: Superluminal snags $60M; AusperBio adds $120M
• Superluminal and AusperBio secured venture capital funding in early 2026. • Superluminal raised $60 million while AusperBio added $120 million to its funding. • These investments provide the necessary capital for biopharma companies to advance drug development and research.
fiercebiotech.com
